Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Comparison of noncoding RNA profiles in RNA from ovarian cancer patient samples

ABSTRACT: We used NCode Human Long Non-coding RNA microarray to study differential expression of noncoding RNAs in tumor samples from patients with ovarian cancer. Normal ovarian tissue samples were used as controls.

ORGANISM(S): Homo sapiens

PROVIDER: GSE74448 | GEO | 2015/12/30

SECONDARY ACCESSION(S): PRJNA300439

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Assessment Of Long Noncoding RNA CCAT1 In Colorectal Cancer Patients

Project description:1. Evaluate the diagnostic value of long noncoding RNA (CCAT1) expression by RT-PCR in peripheral blood in colorectal cancer patients versus normal healthy control personal. 2. Evaluate the clinical utility of detecting long noncoding RNA (CCAT1) expression in diagnosis of colorectal cancer patients & its relation to tumor staging. 3. Evaluate the clinical utility of detecting long noncoding RNA (CCAT1) expression in precancerous colorectal diseases. 4. Compare long noncoding RNA (CCAT1) expression with traditional marker; carcinoembryonic antigen (CEA) and Carbohydrate antigen 19-9 (CA19-9) in diagnosis of colorectal cancer.

| 2330122 | ecrin-mdr-crc

Ovarian Tumor Samples: mixed reference of 106 pooled ovarian samples vs. individual patient ovarian sample

Project description:The goal of the study was to identify molecular subgroups that might predict clinical outcomes in serous epithelial ovarian cancer (EOC) patients. A second objective was to identify potential therapeutic targets for serous EOC based on improved understanding of the molecular diversity of the disease. Ovarian tissues and matched peripheral blood samples were prospectively obtained from sequential patients undergoing planned gynecologic surgery at Cedars-Sinai Medical Center between 1989 and 2005. All patients underwent surgery and received adjuvant chemotherapy with a contemporaneous standard-of-care regimen.

2013-12-26 | GSE51088 | GEO

Ovarian Tumor Samples: mixed reference of 106 pooled ovarian samples vs. individual patient ovarian sample

2013-12-26 | E-GEOD-51088 | biostudies-arrayexpress

Expression analysis of platinum sensitive and resistant epithelial ovarian cancer patient samples.

Project description:The objective of this work was to identify potential cancer biomarkers by analyzing microarray and protein expression data from platinum-sensitive and -resistant ovarian cancer patient samples. The gene expression profiles of the samples were ompared based on platinum sensitivity status and PARP levels.

2018-05-09 | GSE114206 | GEO

Long noncoding RNA and mRNA expression profile in ovarian cancer

Project description:Long noncoding RNA and mRNA expression profile in ovarian cancer

| PRJNA487949 | ENA

Expression profile of 285 ovarian tumour samples

Project description:We used microarrays to profile the expression levels of 285 ovarian samples in order to identify molecular subtypes of the tumour Keywords: disease state analysis

2008-03-01 | GSE9891 | GEO

Gene expression of Ovarian Tumor Samples measured by Agilent microarray

Project description:The goal of the study was to collect ovarian cancer samples for gene expression profiling (n = 529). The data will be used in several publications, the first of which described molecular signatures associated with high-grade serous ovarian cancer subtype

2016-09-30 | GSE74357 | GEO

Discovery and validation of novel protein biomarkers in ovarian cancer patient urine

Project description:Diagnosis of ovarian cancer at an early stage is the most important determinant of survival. Thus, there is a clear need for novel biomarkers to improve diagnostic and prognostics that may better inform on therapeutic strategies. We have conducted a discovery study using label-free quantitative mass spectrometry (LFQ) to identify potential biomarker candidates in urine from individual ovarian cancer patients. LFQ analyses identified 4394 proteins (16397 peptides) in urine samples (n=20), 23 of which were significantly elevated in the malignant patient group compared to patients with benign disease. To validate these changes, we used Parallel Reaction Monitoring (PRM) to investigate their abundance in an independent cohort (n=20) of patient urine samples. Seven of the ten proteins were significantly enriched in the ovarian cancer patient samples; amongst these were established ovarian cancer markers WFDC2 (HE4) and Mesothelin (MSLN), validating our approach. This is the first application of a LFQ-PRM workflow to identify and validate ovarian cancer-specific biomarkers in urine samples.

2018-02-15 | PXD007962 | Pride

Long noncoding RNA, microRNA, and mRNA expression profiles in ovarian cancer

Project description:Long noncoding RNA, microRNA, and mRNA expression profiles in ovarian cancer

| PRJNA487947 | ENA

Gene Expression Analysis of Ovarian Samples

Project description:The Homeobox (HOX) family of genes encodes transcription factors involved in basic developmental processes, most notably during embryogenesis. A possible HOX gene link between development and oncogenesis has recently been described. Dysregulation of HOX genes may be an early event in malignant transformation likely to induce antibody response and thus provide a potential marker for early diagnosis of cancer. Ovarian cancer is characterized by poor early detection and serves as an excellent model system to develop potential markers for early diagnosis. In this study we begin to characterize HOX gene expression in malignant tumors of the ovary and analyze the potential role of HOX genes as biomarkers for early detection of ovarian cancer. Microarray analysis of mRNA from human ovarian tissues was performed on 65 samples of normal, benign, borderline malignant and malignant ovarian tissue. These samples were analyzed using the Affymetrix Human Genome Focus GeneChip (HG-Focus) microarray to distinguish the differential pattern of mRNA expression between the four types of samples. Real-time reverse transcription PCR was utilized to confirm up-regulation of HOX genes as determined by microarray analysis. Our results demonstrate multiple HOX genes to be up-regulated in ovarian cancer. We have shown stepped increase in HOX expression comparing normal, benign neoplastic, and malignant human ovarian tissue samples. This suggests dysregulation of HOX genes may be an early event in malignant transformation and warrants additional studies to validate HOX gene products as potential markers for early detection of ovarian cancer. Keywords: Human Ovarian cancer, HOX, Homeobox, microarray, gene expression

2008-07-31 | GSE4122 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data